Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis

Q: What is the RYTM stock price target?

Take-profit $123.90 (+50.4% upside). Prior stop was $77.66.

Q: What are the risks of investing in RYTM?

Concentration risk — Product: IMCIVREE (setmelanotide); Quality below floor (3.7 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.8), Material insider selling (3 sells, 13.86% of cap); Quality below floor (3.7 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.8), Material insider selling (3 sells, 13.86% of cap).

Q: Is RYTM overvalued or undervalued?

Rhythm Pharmaceuticals, Inc. trades at a P/E of N/A (forward -210.3). TrendMatrix value score: 5.4/10. Overall verdict: Sell.

Q: What do analysts say about RYTM?

22 analysts cover RYTM with a consensus score of 4.3/5. Average price target: $138.

SellVALUE-TRAP 2/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 5 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on IMCIVREE (setmelanotide), an MC4R agonist approved for BBS and certain genetic obesity diseases in the US, EU, UK, Canada, and 25+ countries. As of December 31, 2025, cumulative revenue from... Read more

$82.53+50.4% A.UpsideScore 5.1/10#71 of 158 Biotechnology

Stop $77.66Target $123.90(analyst − 10%)A.R:R 6.5:1

Analyst target$137.67+66.8%15 analysts

$123.90our TP

$82.53price

$137.67mean

$158

Sell if holding. Engine safety override at $82.53: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 6.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Product: IMCIVREE (setmelanotide)

Quality below floor (3.7 < 4.0)

Value-trap signals (2/5): High leverage (D/E 3.8), Material insider selling (3 sells, 13.86% of cap)

Key Metrics

P/E (TTM)—

P/E (Fwd)-210.3

Mkt Cap$5.6B

EV/EBITDA-28.6

Profit Mgn-103.6%

ROE-90.5%

Rev Growth36.9%

Beta2.14

DividendNone

Rating analysts22

Quality Signals

Piotroski F6/9

Options Flow

P/C0.57bullish

IV83%elevated

Max Pain$70-15.2% vs spot

Concentration Risks(10-K Item 1A)

HIGHProductIMCIVREE (setmelanotide)
10-K Item 1A: 'Our operations to date have been primarily focused on developing and commercializing IMCIVREE (setmelanotide) to treat patients living with hyperphagia and severe obesity caused by rare MC4R pathway diseases.'

Material Events(8-K, last 90d)

2026-04-03Item 5.02LOW
Kimberly J. Popovits elected to Rhythm's Board as Class II director effective April 1, 2026; Edward T. Mathers resigned from the Board on the same date. Mathers resignation not due to any disagreement.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.415%0.81

Quality3.715%0.56

Growth10.015%1.50

Momentum1.610%0.16

Sentiment8.010%0.80

Insider Activity3.810%0.38

Peer Rank1.910%0.19

Technical Setup7.15%0.35

Risk Profile3.95%0.20

Catalyst2.55%0.13

Overall (Σ contributions)5.07

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume

0.0

Macd

0.3

Obv

1.0

Ma Position

2.2

Rsi

4.5

Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.6%/30d) — pullback in uptrend, not confirmed weakness

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.0

Value Rank

1.5

Growth Rank

6.1

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 1B/3MEarnings in 5 days

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roe

0.0

Roa

0.0

Operating Margin

0.0

Fcf Quality

0.0

Rule Of 40

3.0

Moat

5.0

Piotroski F

6.7

Current Ratio

8.6

Gross Margin

10.0

Cash-burning: FCF -77% of revenueNo competitive moatRule of 40: -40 (fail)

GatesMomentum 1.6<4.5EARNINGS PROXIMITY 5d<=7dA.R:R 6.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

42 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $80.06Resistance $90.79

Price Targets

$78

$124

A.Upside+50.1%

A.R:R6.5:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (3.7 < 4.0)

! Value-trap signals (2/5): High leverage (D/E 3.8), Material insider selling (3 sells, 13.86% of cap)

! Momentum score 1.6/10 — below 4.5 minimum

Earnings

1/4 beats

Next Earnings2026-05-05 (5d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is RYTM stock a buy right now?

Sell if holding. Engine safety override at $82.53: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 6.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $77.66. Score 5.1/10, moderate confidence.

What is the RYTM stock price target?

Take-profit target: $123.90 (+50.4% upside). Prior stop was $77.66. Stop-loss: $77.66.

What are the risks of investing in RYTM?

Concentration risk — Product: IMCIVREE (setmelanotide); Quality below floor (3.7 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.8), Material insider selling (3 sells, 13.86% of cap).

Is RYTM overvalued or undervalued?

Rhythm Pharmaceuticals, Inc. trades at a P/E of N/A (forward -210.3). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about RYTM?

22 analysts cover RYTM with a consensus score of 4.3/5. Average price target: $138.

What does Rhythm Pharmaceuticals, Inc. do?Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on IMCIVREE (setmelanotide), an MC4R...